The article goes on to mention that ESI will cover Sovaldi for those who have Genotype II or advanced liver disease. Those who are being treated with Sovaldi/Harvoni will continue to be covered as long as they have started treatment before the end of 2014. ESI has a well earned reputation as being difficult to negotiate with as I have detailed in the past during the Walgreen (WAG) negotiation. ESI is trying to prove their value to their customers by trying to keep a lid on costs; I can't fault them for trying. Where I have a problem is the comments that the pill burden is trivial. I suspect we will see clinical failures due to lack of compliance. The second part of the equation is the use of Ribavirin which has a host of nasty side effects. ESI will have to provide Sovaldi to those who have failed previous treatments with Ribavirin due to side effects. The idea that ABBV would take market share from GILD should not come as